88 results about "Blood urate level" patented technology

The present invention provides lactic acid bacteria which are suitable for use for dietary products and pharmaceuticals, and which can suppress the increase of blood uric acid level.

Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2922, were found.

The invention discloses a lactobacillus plantarum UA-416 strain and application thereof, and belongs to the field of functional food microbes. Blanks of lactobacillus plantarum in the effects of lowering uric acid and resisting gout are filled up. According to the lactobacillus plantarum (Lactobacillus plantarum) UA-416 strain provided by the invention, the bacterial strain is already collected inthe China Center for Type Culture Collection (CCTCC) on July 25, 2017; the collection number is CCTCC NO: M2017419. The lactobacillus plantarum UA-416 strain provided by the invention can be used foreffectively lowering the level of blood uric acid, is used for improving the levels of urea nitrogen and creatinine and inhibiting the activity of xanthine oxidase in serum, and has prevention and treatment effects on uricemia or the gout.

The invention discloses an L.plantarum UA149 strain and an application thereof, and belongs to the field of functional food microorganisms. The L.plantarum UA149 strain is deposited in China Typical Culture Collection Center on November 29, 2018 with the preservation number of CCTCC No: M2018842. The strain can be apply to preparing products with a uric acid reducing function or a gout resisting function. Lactic acid bacteria separated and identified from the surface of fleshy plant leaves are taken as research objects, and a new strain of lactic acid bacteria is screened through a large number of experiments. Hyperuricemia model rats are established by potassium oxazinate combined with fructose water, continuous intragastric administration of the lactobacillus plantarum UA149 strain for 14 days can significantly reduce the level of uric acid; and during gout attack, the release of inflammatory factors thromboxane and leukotriene mediated by neutrophils is reduced, the influx of neutrophils into joints is avoided, and the symptoms of redness, swelling, pain, heat and the like are reduced.

The invention discloses a method for building an animal model with hyperuricemia-combined diabetes. The method comprises the following steps: 1) feeding an target animal with fodder containing 10% (by mass) of yeast powder; subjecting the target animal to a lavage with a 4% (by mass) adenine water solution according to the following dosage of 100 milligram of adenine per day per kilogram of body weight until the blood uric acid level of the target animal starts falling; 2) halving the dosage of the adenine water solution in step 1), subjecting the target animal to a subcutaneous injection with an oteracil potassium emulsion twice a day according to the following dosage of 100 milligram of oteracil potassium emulsion per day per kilogram of body weight until the target animal shows clinical symptoms of diabetes, and then obtaining the animal model with the hyperuricemia-combined diabetes. The method builds the animal model with the hyperuricemia-combined diabetes for the first time, the animal model has typical disease symptoms, the quantity index has statistical significance, and studies such as glucose clamp test and immunohistochemistry also prove that the modeling is successful. Therefore, the method for building the animal model with the hyperuricemia-combined diabetes is a reliable and practical technique.

Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.

The invention relates to a PEGylation urate oxidase compound as well as the preparation method thereof and the preparation of PEGylation urate oxidase compound as well as the application thereof, particularly relates to a PEGylation urate oxidase compound which has extremely low immunogenicity and anaphylaxis, can be applied repetitively and has a long acting as well as the preparation method thereof and the preparation of PEGylationurate oxidasee compound as well as the application thereof. The invention adopts a modification method which has high selectivity to a N-terminal of a urate oxidase, which means that PEG active ester is connected with the N-terminal of the urate oxidase by covalence bond, the uniformity of products is greatly improved, the products are easy to be purified, the activity of the purified products can be better preserved and the immunogenicity of prototype protein of the urate oxidase can be reduced obviously. The PEGylation urate oxidase compound can prevent systemic anaphylaxis when applied, can be applied repetitively and has the efficacy of treating and preventing gout, reducing the level of serum uric acid, preventing tumor lysis syndrome and improving the renal function.

The invention relates to the field of microorganisms, and discloses lactobacillus fermentum capable of reducing blood uric acid. The strain is named 2644 strain, and is preserved at the China GeneralMicrobiological Culture Collection Center on 19th, November, 2018, and a microbial preservation number is CGMCC NO.16754; and the preservation authority address is NO.3 1# Courtyard, Beichen West Road, Chaoyang District, Beijing, and the microorganism is classified and named Lactobacillus fermentum. The strain can effectively reduce the content of the blood uric acid; and not only can intake of exogenous purines be reduced, but also discharge of internal uric acid from an intestinal tract can be promoted so that the blood uric acid level of a body can be more effectively controlled.

The invention relates to the field of microorganisms, and discloses lactobacillus rhamnosus capable of reducing uric acid. The lactobacillus rhamnosus is named as 1155, is preserved in microbial culture collection management committee of China general microbiological culture collection on 4th, January, 2016, with the microbial preservation number being CGMCC NO.11955; and the preservation organization address is yard No.3, west Beichen road, Chaoyang district, Beijing City, and the microbial classification name is lactobacillus rhamnosus. According to strains disclosed by the invention, the content of the uric acid can be effectively reduced, discharging of uric acid in the body from an intestinal tract also can be promoted, intake of exogenous purine substances also can be reduced, and auric acid level of an organism can be controlled more effectively.

The invention discloses a duplication method of rat acute or persistent hyperuricemia model which comprises, (1) selecting male, female healthy rats with the specie of SD and Wistar and 150-450g of body weight, simultaneously administering purines by 100-2000 mg/kg and uric acid depressant by 5-1000mg/kg through stomach filling, hypodermic injection or abdominal cavity injection, (2) after 5-24 hours, administering the rats by the same mode and medicament dose, (3) administering the rats daily continually according to the step (1) and (2), continuing administration for one to two weeks.

The invention discloses lactobacillus fermentum for preventing and treating hyperuricemia as well as a composition and application thereof, wherein the lactobacillus fermentum GF1800 for preventing and treating hyperuricemia has the preservation number of CCTCC NO:M 2021984. The lactobacillus fermentum GF1800 is high in biological activity and strong in acid production capacity, can effectively inhibit the activity of pathogenic microorganisms and xanthine oxidase, can tolerate gastric acid and cholate, has a remarkable degradation effect on nucleoside substances, uric acid, cholesterol, nitrite and the like, can efficiently inhibit intake of exogenous uric acid and increase of endogenous uric acid, can obviously reduce the blood uric acid level of hyperuricemia, and meanwhile, improves intestinal and kidney structural injury and inflammatory response. The invention further discloses a composition containing the lactobacillus fermentum GF1800 and a strain metabolite and postbiotics of the lactobacillus fermentum GF1800 and an application of the lactobacillus fermentum GF1800 and the postbiotics of the lactobacillus fermentum GF1800 to preparation of functional food or medicine for preventing and treating hyperuricemia or/and gout, degrading nucleoside, inhibiting xanthine oxidase, reducing cholesterol, degrading nitrite and inhibiting pathogenic bacteria.

The invention belongs to the technical field of food preparation, and particularly relates to a fructus gardeniae and poria cocos composite beverage and a preparation method thereof. The fructus gardeniae and poria cocos composite beverage is prepared from the following raw materials of fructus gardeniae, poria cocos, villous amomum fruits, chicory, mulberry leaves, corn stigma, polished glutinousrice, Chinese yams, cherries, carrots, celery, papayas, lemons, potassium citrate, sodium citrate, water and lactic acid bacteria. The fructus gardeniae and poria cocos composite beverage is suitablefor patients suffering from hyperuricaemia and gout, in multiple manners for invigorating spleen, eliminating dampness, promoting drainage of uric acid, reducing uric acid and the like, the blood uric acid level can be reduced in multiple target points, and the breaking out of the gout can be alleviated.

The invention discloses a method for constructing an animal model of hyperuricemia induced renal interstitial fibrosis. The method comprises the following steps of: feeding an objective animal by using a feed containing 10 percent by mass of yeast powder; performing intragastric administration on the objective animal by using an aqueous solution of adenine according to the following consumption: 100mg adenine/ day/ kg (weight), till the blood uric acid level of the objective animal rises; and after renal interstitial fibrosis appears at the kidney, obtaining the animal model of the hyperuricemia induced renal interstitial fibrosis. By adopting the method, the animal model of the hyperuricemia induced renal interstitial fibrosis is established for the first time, and the model is significant for researching related diseases.

The invention provides a traditional Chinese medicine composition for treating uarthritis and a preparation method thereof and relates to the field of the traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of radix achyranthis bidentatae, 5-25 parts of astragalus membranaceus, 3-20 parts of poria cocos, 5-15 parts of bighead atractylodes rhizome, 10-30 parts of cortex acanthopanacis, 10-20 parts of stephania terandra, 8-20 parts of vitex negundo roots, 3-12 parts of akebiaquinata, 10-25 parts of kudzu vine roots, 5-15 parts of cortex lycii radicis, 8-20 parts of ginseng and 10-25 parts of wolfberry. The preparation method comprises the following steps: frying astragalus membranaceus, bighead atractylodes rhizome and kudzu vine roots with bran, then adding water and decocting with the rest raw materials, carrying out filtering and concentrating and adding a carrier to acquire any medicine preparation in pharmaceutics. The traditional Chinese medicine prepared according to the invention can effectively reduce the blood uric acid level, the total effective rate reaches up to 97.55% and the side effect is small.

The present invention relates to a compound having an URAT1 inhibitory activity, and to an URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition containing the compound.

More specifically, the present invention relates to a compound represented by the formula (I):

wherein

• • R¹ is -Q¹-A¹ or the like; R² is a hydrogen atom, a halogen atom, a lower alkyl group or the like; W¹, W², W³ and W⁴ are each independently a nitrogen atom or a methine group optionally having substituents, or the like; X and Y are each a single bond, an oxygen atom or the like; Z is a hydroxyl group or COOR³ or the like.

The invention relates to a novel pharmacological action of an extract of the semen coicis which is a Chinese herbal medicine, and particularly relates to an application of the extract of the semen coicis to the reduction of the blood uric acid of a patient with hyperuricemia or gout. The extract of the semen coicis has the function of significantly reducing the level of the blood uric acid of a quail with the uric-acid induced hyperuricemia. A process for preparing an oral preparation from the semen coicis comprises the following steps: heating the semen coicis, extracting the semen coicis repeatedly for 1-3 times by taking the effective components including the ethyl acetate and the aqueous ethanol as extracting solvents, removing the dregs of a decoction, removing the solvents at normal pressure or reduced pressure, and adding auxiliary materials. The method for preparing the traditional Chinese medicine from the semen coicis is simple, the extract of the semen coicis can be prepared into various preparations, and the traditional Chinese medicine prepared from the extract of the semen coicis is effective in reducing the blood uric acid.

The invention provides pharmaceutical composition for reducing blood uric acid level. The pharmaceutical composition is prepared from the following bulk drugs by weight: 17-23 parts of ramulus cinnamomi, 17-23 parts of rhizoma curcumae longae, 17-23 parts of radix stephaniae tetrandrae, 17-23 parts of semen plantaginis, 7-13 parts of appendiculate cremastra pseudobulb and 12-18 parts of fructus evodiae. The invention further provides a preparation method and an application of the composition. The composition is reasonable in compatibility, has obvious effect on reducing the blood uric acid level and can be used for treating hyperuricemia and gouty arthritis, and a novel drug is provided clinically.

The invention discloses a traditional Chinese medicine composition for treating gouty arthritis. An active ingredient of the traditional Chinese medicine composition for treating the gouty arthritis is prepared from the following raw material medicines in parts by weight: 30-60 parts of rhizoma smilacis glabrae, 20-40 parts of radix astragali, 5-10 parts of radix platycodonis, 10-30 parts of rhizoma alismatis, 20-40 parts of semen plantaginis and 15-40 parts of herba epimedii. The traditional Chinese medicine composition for treating the gouty arthritis, disclosed by the invention, has the advantages of simple composition, good safety, no obvious toxic and side effects on lever and kidney, and obvious effect of reducing uric acid level and protecting the kidney. The traditional Chinese medicine composition for treating the gouty arthritis, disclosed by the invention, has the advantages that effect of the traditional Chinese medicine composition in reducing the uric acid level and improving inflammatory marks is equivalent to the effect of uric-acid-lowering drug benzbromarone; and the effect of the traditional Chinese medicine composition in improving glomerular filtration rate issuperior to the effect of the uric-acid-lowering drug benzbromarone.

The invention belongs to the technical field of experimental model building, and relates to a duplication method of a rat continuous hyperuricemia model. The method comprises the following four steps:animal selection, adaptive feeding, model building and model application; the method comprises the following specific steps: performing adaptive feeding on selected healthy rats in a clean animal feeding room for 1 week, and ensuring that rats with normal morphological characteristics are used for building a model; and injecting 500 mg.kg<-1> uricase inhibitor oteracil potassium to the rats withnormal morphological characteristics at room temperature every day in an intraperitoneal injection administration manner, and meanwhile giving 10 percent fructose drinking water and sufficient diet for 24 hours without interruption. Administration to rats and molding are continuously performed every day, and administration is continued for 3 weeks, a sample rat hyperuricemia model is obtained; andthe built rat hyperuricemia model is applied, so that a hypeluricemia model with typical disease characteristics is obtained. The method is simple to operate, and short in duplication cycle, can ensure that the hyperuricemia level of the rats can be obviously improved, can further properly simulate the clinical features of hyperuricemia, and has a good application prospect.

The invention discloses a method for constructing a spontaneous hyperuricemia mouse model. The method for constructing the spontaneous hyperuricemia mouse model provided by the invention comprises the following step: knocking out urate oxidase genes of a target mouse by utilizing transcription activator-like effector nuclease to obtain a homozygote mouse from which the urate oxidase genes are knocked out, namely the spontaneous hyperuricemia mouse model. Experiments prove that the serum uric acid level of the spontaneous hyperuricemia mouse model obtained by the method disclosed by the invention is 3-4 times that of a wild type mouse and achieves the hyperuricemia level, and the pathogenesis of spontaneous hyperuricemia is better simulated. In addition, as the serum uric acid level of the mouse model obtained by the method disclosed by the invention is lower than the ultrahigh-level serum uric acid value reported in the previous literature, the lethal hyperuricemia does not exist, and the survival time of the mouse is long, so that long-term experiment of the mouse is facilitated.

The invention relates to use of pterostilbene in preparing a medicine for preventing and treating high uric acid nephropathy, and belongs to the field of medicine, and provides use of the pterostilbene or a pharmaceutically acceptable salt thereof in preparing the medicine for treating and/or preventing the high uric acid nephropathy. Experimental results show that the pterostilbene can significantly reduce the level of serum uric acid, inhibits renal interstitial fibrosis, can significantly reduce the expression of fibrosis-related proteins such as alpha-SMA, collagenI, collagenIV and fibronectin, has a definite therapeutic effect on the high uric acid nephropathy, and provides a new option for clinical medication.

The invention provides prescriptions for preventing and treating gout. A medicine treating the gout comprises, by weight, the following ingredients: 10g of radix stephaniae tetrandrae, 30g of mulberry twig, 30g of kudzuvine root, 3g of wild ginger, 12g of mistletoe, 10g of notopterygium, 10g of rhizoma alismatis, 10g of hiraute shiny bugleweed herb, 3g of safflower, 10g of phellodendron amurense, 10g of lithospermum purpurocaeruleumm, 3g of scorpion, 20g of plantain seed, 30g of shinyleaf pricklyash root and 15g of kadsura pepper stem. A medicine preventing the gout comprises, by weight, the following ingredients: 10g of radix stephaniae tetrandrae, 30g of mulberry twig, 30g of kudzuvine root, 10g of salvia miltiorrhiza, 3g of wild ginger, 10g of notopterygium, 15g of gentiana macrophylla, 15g of mistletoe, 10g of himalayan teasel root, 10g of dandelion, 3g of scorpion, 10g of phellodendron amurense, 15g of achyranthes bidentata, 15g of plantain seed and 30g of shinyleaf pricklyash root. The medicines are orally administered, six pills are taken each time, and the medicines are taken three times each day, can have the effects of anti-inflammation, analgesia, diuresis and circulation promoting and stasis removing, have obvious therapeutic effects on redness and swelling and heat pain of joints, and can greatly reduce level of blood uric acid.

The invention provides a compound probiotic composition. The compound probiotic composition is prepared from lactobacillus casei, two bifidobacterium lactis strains, lactobacillus plantarum and lactobacillus rhamnosus. By analyzing the change of related indexes in the blood of the patient before and after intervention of the compound probiotic composition, the compound probiotic composition can achieve the effect of relieving or treating the hyperuricemia patient by reducing the blood uric acid level and related metabolic syndrome index level of the hyperuricemia patient.

The invention discloses a composition for reducing blood uric acid of hyperuricemia. The composition is prepared from the following ingredients in parts by weight: 25 to 100 parts of orange extracts,50 to 200 parts of grape seed extracts, 5 to 20 parts of vitamin E, 2.5 to 10 parts of vitamin B6, 5 to 20 parts of nicotinic acid, 50 to 200 parts of zinc gluconate and 500 to 2000 parts of potassiumcitrate. The animal effect evaluation result shows that the composition provided by the invention can obviously improve the urine pH of a rat with hyperuricemia; the 24h urine discharge quantity is obviously improved; the serum total anti-oxidization capability is improved; the lipid peroxide content is obviously reduced; the serum xanthine oxidase activity is reduced; the blood uric acid level is obviously reduced. The animal experiment result shows that when a proper quantity of the composition is supplied to the model rat with the hyperuricemia, the body anti-oxidization capability can beobviously improved; the blood uric acid is reduced.

The invention relates to the field of medicine, and particularly provides application of cobra venom or an extract thereof to preparation of a medicament for reducing uric acid and/or resisting to gouty arthritis. According to the invention, the cobra venom can effectively reduce the blood uric acid level of a hyperuricemic mouse, meanwhile, has an obvious improvement effect on the gouty arthritis, and can repair the joint injury caused by sodium urate deposition, reduce the joint swelling rate, improve the joint synovial tissue thickening condition, reduce inflammatory cell infiltration, protect cartilage cells; and clinical experiments show that cobra neurotoxin can quickly eliminate subcutaneous gout calculi of gout patients, lumps disappear after the cobra venom is injected into the patients for three days, and no side effect exists. In conclusion, the Chinese cobra venom has the effect of repairing gouty arthritis while reducing uric acid, and can be used as a medicament for treating gout.